BAM Capital
Latest statistics and disclosures from BAM Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, Pharmasset, IWM, BIIB, Targacept, and represent 60.61% of BAM Capital's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$22M), Pharmasset (+$9.6M), IWM (+$9.0M), NFLX (+$5.7M), BIIB (+$5.6M), Medivation (+$5.3M), Barclays Bk Plc ipth s^p vix, Targacept, Research In Motion, Delcath Sys.
- Started 15 new stock positions in Barclays Bk Plc ipth s^p vix, NPS Pharmaceuticals, AFFY, Inhibitex, INC Ventrus Biosciences, shares Agenus, NFLX, Research In Motion, Delcath Sys, IDCC. Medivation, Delcath Sys, ACAD, BioSante Pharmaceuticals, IWM.
- Reduced shares in these 10 stocks: UTHR (-$25M), AMRN, Gen-Probe Incorporated, Delcath Systems, Elan Corporation, VirnetX Holding Corporation, Vivus, BBY, Ariad Pharmaceuticals, AVEO Pharmaceuticals.
- Sold out of its positions in AMRN, Ariad Pharmaceuticals, AVEO Pharmaceuticals, BBY, BioMimetic Therapeutics, Forest Laboratories, Gen-Probe Incorporated, Human Genome Sciences, Onyx Pharmaceuticals, Orexigen Therapeutics. Raptor Pharmaceutical, VirnetX Holding Corporation.
- BAM Capital was a net buyer of stock by $18M.
- BAM Capital has $97M in assets under management (AUM), dropping by -2.74%.
- Central Index Key (CIK): 0001355197
Portfolio Holdings for BAM Capital
BAM Capital holds 30 positions in its portfolio as reported in the September 2011 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p 500 Etf (SPY) | 24.4 | $24M | +950% | 210k | 113.17 |
|
| Pharmasset | 11.7 | $11M | +528% | 138k | 82.37 |
|
| iShares Russell 2000 Index (IWM) | 9.2 | $9.0M | NEW | 140k | 64.25 |
|
| Biogen Idec (BIIB) | 8.9 | $8.7M | +179% | 93k | 93.15 |
|
| Targacept | 6.4 | $6.2M | +59% | 413k | 15.00 |
|
| Netflix (NFLX) | 5.8 | $5.7M | NEW | 50k | 113.28 |
|
| Medivation | 5.5 | $5.3M | NEW | 313k | 16.97 |
|
| Keryx Biopharmaceuticals | 5.2 | $5.0M | +41% | 1.7M | 3.00 |
|
| Vivus | 4.5 | $4.4M | -40% | 542k | 8.06 |
|
| Barclays Bk Plc ipth s^p vix | 4.4 | $4.3M | NEW | 80k | 53.37 |
|
| Elan Corporation | 2.5 | $2.4M | -58% | 231k | 10.53 |
|
| Research In Motion | 2.1 | $2.1M | NEW | 102k | 20.31 |
|
| Delcath Sys | 1.9 | $1.8M | NEW | 551k | 3.34 |
|
| Delcath Sys | 1.8 | $1.7M | NEW | 512k | 3.34 |
|
| Acorda Therapeutics | 1.2 | $1.2M | +79% | 60k | 20.00 |
|
| XenoPort | 1.0 | $941k | +2% | 161k | 5.86 |
|
| United Therapeutics Corporation (UTHR) | 0.8 | $783k | -96% | 21k | 37.45 |
|
| InterDigital (IDCC) | 0.5 | $521k | NEW | 11k | 46.52 |
|
| Dendreon Corporation | 0.4 | $386k | +83% | 43k | 9.00 |
|
| Eli Lilly & Co. (LLY) | 0.3 | $285k | 7.7k | 37.01 |
|
|
| Affymax (AFFY) | 0.3 | $268k | NEW | 60k | 4.48 |
|
| NPS Pharmaceuticals | 0.2 | $235k | NEW | 36k | 6.50 |
|
| INC Ventrus Biosciences | 0.2 | $236k | NEW | 26k | 9.02 |
|
| Inhibitex | 0.2 | $198k | NEW | 80k | 2.46 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.2 | $164k | NEW | 152k | 1.08 |
|
| shares Agenus | 0.1 | $129k | NEW | 274k | 0.47 |
|
| Delcath Systems | 0.1 | $97k | -97% | 29k | 3.36 |
|
| Genvec | 0.1 | $100k | -9% | 35k | 2.86 |
|
| BioSante Pharmaceuticals | 0.1 | $68k | NEW | 30k | 2.27 |
|
| GTx | 0.1 | $52k | +24% | 15k | 3.37 |
|
Past Filings by BAM Capital
SEC 13F filings are viewable for BAM Capital going back to 2010
- BAM Capital 2011 Q3 filed Nov. 14, 2011
- BAM Capital 2011 Q2 filed Aug. 15, 2011
- BAM Capital 2011 Q1 filed May 16, 2011
- BAM Capital 2010 Q4 filed Feb. 14, 2011